Which has stronger earnings & valuation, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abbott Laboratories $44.33B 3.35 $6.52B $3.57 23.91 DexCom $4.66B 6.10 $836.30M $2.34 31.51

Is ABT or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity. Company Net Margins Return on Equity Return on Assets Abbott Laboratories 13.90% 17.62% 10.01% DexCom 19.31% 33.33% 13.19%

Does the media favor ABT or DXCM?

In the previous week, Abbott Laboratories had 10 more articles in the media than DexCom. MarketBeat recorded 37 mentions for Abbott Laboratories and 27 mentions for DexCom. DexCom's average media sentiment score of 1.19 beat Abbott Laboratories' score of 0.94 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor ABT or ISRG?

In the previous week, Intuitive Surgical had 11 more articles in the media than Abbott Laboratories. MarketBeat recorded 48 mentions for Intuitive Surgical and 37 mentions for Abbott Laboratories. Intuitive Surgical's average media sentiment score of 1.27 beat Abbott Laboratories' score of 0.94 indicating that Intuitive Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive Intuitive Surgical 39 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABT or TSLA?

In the previous week, Tesla had 185 more articles in the media than Abbott Laboratories. MarketBeat recorded 222 mentions for Tesla and 37 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.94 beat Tesla's score of 0.80 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive Tesla 118 Very Positive mention(s) 34 Positive mention(s) 39 Neutral mention(s) 21 Negative mention(s) 9 Very Negative mention(s) Positive

Is ABBV or ABT more profitable?

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Abbott Laboratories 13.90% 17.62% 10.01%

Does the media favor ABBV or ABT?

In the previous week, AbbVie had 18 more articles in the media than Abbott Laboratories. MarketBeat recorded 55 mentions for AbbVie and 37 mentions for Abbott Laboratories. AbbVie's average media sentiment score of 1.06 beat Abbott Laboratories' score of 0.94 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 37 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media refer more to BSX or ABT?

In the previous week, Boston Scientific had 19 more articles in the media than Abbott Laboratories. MarketBeat recorded 56 mentions for Boston Scientific and 37 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.94 beat Boston Scientific's score of 0.63 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 28 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Positive Abbott Laboratories 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive

Abbott Laboratories (ABT) Competitors

$85.36 -0.94 (-1.09%)

Closing price 05/29/2026 03:59 PM Eastern

Extended Trading

$85.55 +0.20 (+0.23%)

As of 05/29/2026 07:59 PM Eastern

Compare

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

Should you buy Abbott Laboratories stock or one of its competitors? MarketBeat compares Abbott Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), and Boston Scientific (BSX).

How does Abbott Laboratories compare to DexCom?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
DexCom	19.31%	33.33%	13.19%

Abbott Laboratories presently has a consensus price target of $119.09, suggesting a potential upside of 39.52%. DexCom has a consensus price target of $82.42, suggesting a potential upside of 11.77%. Given Abbott Laboratories' higher possible upside, equities research analysts clearly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.35	$6.52B	$3.57	23.91
DexCom	$4.66B	6.10	$836.30M	$2.34	31.51

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abbott Laboratories has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

In the previous week, Abbott Laboratories had 10 more articles in the media than DexCom. MarketBeat recorded 37 mentions for Abbott Laboratories and 27 mentions for DexCom. DexCom's average media sentiment score of 1.19 beat Abbott Laboratories' score of 0.94 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

DexCom beats Abbott Laboratories on 10 of the 16 factors compared between the two stocks.

How does Abbott Laboratories compare to Intuitive Surgical?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Abbott Laboratories presently has a consensus target price of $119.09, indicating a potential upside of 39.52%. Intuitive Surgical has a consensus target price of $576.71, indicating a potential upside of 35.83%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.35	$6.52B	$3.57	23.91
Intuitive Surgical	$10.06B	14.94	$2.86B	$8.25	51.47

Intuitive Surgical has a net margin of 28.15% compared to Abbott Laboratories' net margin of 13.90%. Abbott Laboratories' return on equity of 17.62% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Intuitive Surgical	28.15%	15.98%	14.07%

Abbott Laboratories has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

In the previous week, Intuitive Surgical had 11 more articles in the media than Abbott Laboratories. MarketBeat recorded 48 mentions for Intuitive Surgical and 37 mentions for Abbott Laboratories. Intuitive Surgical's average media sentiment score of 1.27 beat Abbott Laboratories' score of 0.94 indicating that Intuitive Surgical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Intuitive Surgical	39 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Intuitive Surgical beats Abbott Laboratories on 10 of the 16 factors compared between the two stocks.

How does Abbott Laboratories compare to Tesla?

Abbott Laboratories (NYSE:ABT) and Tesla (NASDAQ:TSLA) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Abbott Laboratories currently has a consensus price target of $119.09, indicating a potential upside of 39.52%. Tesla has a consensus price target of $395.20, indicating a potential downside of 9.31%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than Tesla.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Tesla	5 Sell rating(s)	17 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.34

Abbott Laboratories has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Tesla has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

In the previous week, Tesla had 185 more articles in the media than Abbott Laboratories. MarketBeat recorded 222 mentions for Tesla and 37 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.94 beat Tesla's score of 0.80 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Tesla	118 Very Positive mention(s)	34 Positive mention(s)	39 Neutral mention(s)	21 Negative mention(s)	9 Very Negative mention(s)	Positive

Abbott Laboratories has higher earnings, but lower revenue than Tesla. Abbott Laboratories is trading at a lower price-to-earnings ratio than Tesla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.35	$6.52B	$3.57	23.91
Tesla	$94.83B	17.26	$3.79B	$1.09	399.81

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 66.2% of Tesla shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 19.9% of Tesla shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abbott Laboratories has a net margin of 13.90% compared to Tesla's net margin of 3.95%. Abbott Laboratories' return on equity of 17.62% beat Tesla's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Tesla	3.95%	4.89%	2.93%

Summary

Abbott Laboratories beats Tesla on 10 of the 16 factors compared between the two stocks.

How does Abbott Laboratories compare to AbbVie?

AbbVie (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Abbott Laboratories has lower revenue, but higher earnings than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	6.29	$4.23B	$2.03	107.30
Abbott Laboratories	$44.33B	3.35	$6.52B	$3.57	23.91

70.2% of AbbVie shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Abbott Laboratories	13.90%	17.62%	10.01%

AbbVie currently has a consensus price target of $253.43, indicating a potential upside of 16.34%. Abbott Laboratories has a consensus price target of $119.09, indicating a potential upside of 39.52%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 3.0%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Abbott Laboratories has increased its dividend for 54 consecutive years.

AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

In the previous week, AbbVie had 18 more articles in the media than Abbott Laboratories. MarketBeat recorded 55 mentions for AbbVie and 37 mentions for Abbott Laboratories. AbbVie's average media sentiment score of 1.06 beat Abbott Laboratories' score of 0.94 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	37 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does Abbott Laboratories compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Boston Scientific presently has a consensus price target of $87.46, indicating a potential upside of 81.00%. Abbott Laboratories has a consensus price target of $119.09, indicating a potential upside of 39.52%. Given Boston Scientific's higher possible upside, equities research analysts plainly believe Boston Scientific is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	0 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.86
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Boston Scientific has a net margin of 17.29% compared to Abbott Laboratories' net margin of 13.90%. Boston Scientific's return on equity of 19.17% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
Abbott Laboratories	13.90%	17.62%	10.01%

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Boston Scientific has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Abbott Laboratories has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.58	$2.90B	$2.39	20.22
Abbott Laboratories	$44.33B	3.35	$6.52B	$3.57	23.91

In the previous week, Boston Scientific had 19 more articles in the media than Abbott Laboratories. MarketBeat recorded 56 mentions for Boston Scientific and 37 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.94 beat Boston Scientific's score of 0.63 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	28 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	4 Very Negative mention(s)	Positive
Abbott Laboratories	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Abbott Laboratories beats Boston Scientific on 9 of the 17 factors compared between the two stocks.

Get Abbott Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABT vs. The Competition

Export

Metric	Abbott Laboratories	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$149.10B	$8.29B	$6.58B	$23.19B
Dividend Yield	2.94%	2.54%	2.68%	4.09%
P/E Ratio	23.91	15.85	21.59	30.62
Price / Sales	3.35	8.37	561.77	24.75
Price / Cash	12.24	17.57	27.44	19.43
Price / Book	2.81	3.69	10.04	4.70
Net Income	$6.52B	$224.05M	$3.56B	$1.07B
7 Day Performance	-2.36%	3.72%	2.85%	1.14%
1 Month Performance	-5.94%	4.14%	4.59%	1.26%
1 Year Performance	-36.15%	3.90%	37.62%	28.06%

Abbott Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABT Abbott Laboratories	4.9312 of 5 stars	$85.36 -1.1%	$119.09 +39.5%	-36.1%	$149.10B	$44.33B	23.91	115,000	Trending News Analyst Forecast
DXCM DexCom	4.4199 of 5 stars	$72.10 flat	$82.21 +14.0%	-14.2%	$27.82B	$4.66B	30.81	11,000	Analyst Forecast Insider Trade
ISRG Intuitive Surgical	4.1647 of 5 stars	$438.10 flat	$579.33 +32.2%	-23.0%	$155.16B	$10.06B	53.10	17,021	Trending News Analyst Forecast
TSLA Tesla	3.0016 of 5 stars	$426.01 flat	$395.20 -7.2%	+24.8%	$1.60T	$94.83B	390.83	134,785	Trending News
ABBV AbbVie	4.8316 of 5 stars	$216.02 +0.1%	$253.43 +17.3%	+17.4%	$381.10B	$61.16B	106.41	57,000	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABT) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Competitors

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

How does Abbott Laboratories compare to DexCom?

Summary

How does Abbott Laboratories compare to Intuitive Surgical?

Summary

How does Abbott Laboratories compare to Tesla?

Summary

How does Abbott Laboratories compare to AbbVie?

Summary

How does Abbott Laboratories compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT vs. The Competition

Abbott Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Competitors

ABT vs. DXCM, ISRG, TSLA, ABBV, and BSX

How does Abbott Laboratories compare to DexCom?

Is ABT or DXCM more profitable?

Do analysts prefer ABT or DXCM?

Which has stronger earnings & valuation, ABT or DXCM?

Do institutionals and insiders have more ownership in ABT or DXCM?

Which has more risk & volatility, ABT or DXCM?

Does the media favor ABT or DXCM?

Summary

How does Abbott Laboratories compare to Intuitive Surgical?

Do analysts prefer ABT or ISRG?

Which has better earnings & valuation, ABT or ISRG?

Is ABT or ISRG more profitable?

Which has more risk and volatility, ABT or ISRG?

Does the media favor ABT or ISRG?

Do institutionals & insiders believe in ABT or ISRG?

Summary

How does Abbott Laboratories compare to Tesla?

Do analysts rate ABT or TSLA?

Which has more risk and volatility, ABT or TSLA?

Does the media favor ABT or TSLA?

Which has better valuation and earnings, ABT or TSLA?

Do institutionals and insiders believe in ABT or TSLA?

Is ABT or TSLA more profitable?

Summary

How does Abbott Laboratories compare to AbbVie?

Which has higher earnings and valuation, ABBV or ABT?

Do insiders & institutionals have more ownership in ABBV or ABT?

Is ABBV or ABT more profitable?

Do analysts prefer ABBV or ABT?

Is ABBV or ABT a better dividend stock?

Which has more risk and volatility, ABBV or ABT?

Does the media favor ABBV or ABT?

Summary

How does Abbott Laboratories compare to Boston Scientific?

Do analysts recommend BSX or ABT?

Is BSX or ABT more profitable?

Do insiders & institutionals believe in BSX or ABT?

Which has more risk & volatility, BSX or ABT?

Which has better earnings and valuation, BSX or ABT?

Does the media refer more to BSX or ABT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT vs. The Competition

Abbott Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools